Search explainers, questions, and medicine profiles.
The publication’s independent editorial identity. Research and editorial tools assist evidence review. No individual clinician or professional credential is claimed.
How we workA walking plan can support health and daily function without a magic step target or a promised weight-loss number.
Tirzepatide’s evidence spans weight management and selected health outcomes; brand, country, and study population still matter.
A controlled feeding experiment offers causal evidence about the diets it tested, while leaving important everyday questions open.
A brief record of your goals, treatment history, medicines, and practical concerns can make a weight conversation more specific.
A slowing weight trend can reflect changing energy needs and appetite feedback. Review the pattern before making a harsher plan.
Separate semaglutide’s product-specific approvals from the weight-loss and cardiovascular trials that support particular uses.
Read the population, comparator, duration, analysis, and harms before deciding what a weight-loss headline really means.
Protein matters, but more is not a universal solution. Pair food planning with activity, function, and an individualized target.
An eating window can organize a routine. Whether it adds a special weight-loss benefit is a separate research question.
Survodutide has new Phase 3 obesity evidence, including a diabetes trial. It remains separate from an approved prescription and from liver-disease outcomes.
